Albert Bourla, Pfizer CEO (Evan Vucci/AP Images)

Covid-19 roundup: Pfiz­er to sup­ply US with 200M more vac­cines as UK study finds high­er an­ti­bod­ies in 8-10 week in­ter­vals

The US gov­ern­ment has pur­chased 200 mil­lion more dos­es of the Pfiz­er/BioN­Tech vac­cine, the com­pa­nies an­nounced Fri­day morn­ing.

Pfiz­er and BioN­Tech ex­pect to de­liv­er 110 mil­lion of the ad­di­tion­al dos­es by Dec. 31, with the re­main­ing 90 mil­lion dos­es to be de­liv­ered no lat­er than April 30, 2022.

“Un­der this con­tract, the U.S. Gov­ern­ment is pay­ing ~$24 a dose for the Pfiz­er-BioN­Tech COVID-19 Vac­cine. The price for this or­der ac­counts for the ad­di­tion­al in­vest­ment nec­es­sary to pro­duce, pack­age and de­liv­er new for­mu­la­tions of the vac­cine, as well as the in­creased cost as­so­ci­at­ed with de­liv­er­ing the vac­cine in small­er pack sizes to fa­cil­i­tate de­liv­ery at in­di­vid­ual provider of­fices, in­clud­ing pe­di­a­tri­cians,” a Pfiz­er spokesman told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.